NewAmsterdam Pharma (NASDAQ:NAMS) Announces Quarterly Earnings Results

NewAmsterdam Pharma (NASDAQ:NAMS) posted its earnings results on Wednesday. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23), FiscalAI reports. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.

NewAmsterdam Pharma Stock Down 3.9%

NewAmsterdam Pharma stock traded down $1.40 during mid-day trading on Thursday, hitting $34.37. 699,936 shares of the stock were exchanged, compared to its average volume of 683,618. The stock has a market capitalization of $3.90 billion, a price-to-earnings ratio of -16.78 and a beta of 0.06. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $42.00. The firm’s fifty day simple moving average is $34.03 and its two-hundred day simple moving average is $32.43.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 32,612 shares of the company’s stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total transaction of $1,037,061.60. Following the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at approximately $774,425.40. This represents a 57.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $33.25, for a total value of $199,500.00. Following the completion of the transaction, the insider directly owned 73,481 shares in the company, valued at $2,443,243.25. This represents a 7.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 298,647 shares of company stock valued at $10,236,050. 20.84% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Institutional investors have recently modified their holdings of the company. Empowered Funds LLC acquired a new stake in NewAmsterdam Pharma in the 4th quarter valued at $85,000. XTX Topco Ltd lifted its stake in shares of NewAmsterdam Pharma by 1,714.1% in the fourth quarter. XTX Topco Ltd now owns 137,492 shares of the company’s stock valued at $4,823,000 after buying an additional 129,913 shares in the last quarter. Virtus Investment Advisers LLC grew its holdings in shares of NewAmsterdam Pharma by 32.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 7,142 shares of the company’s stock valued at $251,000 after buying an additional 1,731 shares during the last quarter. Twinbeech Capital LP bought a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $961,000. Finally, Millennium Management LLC acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth about $8,931,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NAMS has been the subject of several research reports. Stifel Nicolaus increased their price objective on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Needham & Company LLC increased their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. The Goldman Sachs Group upped their target price on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a report on Tuesday, December 2nd. Finally, Royal Bank Of Canada lifted their price target on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $47.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.